Focus Financial Network Inc. Buys 172 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Focus Financial Network Inc. grew its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,440 shares of the medical equipment provider’s stock after purchasing an additional 172 shares during the period. Focus Financial Network Inc.’s holdings in Lantheus were worth $336,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of LNTH. Kestra Investment Management LLC acquired a new position in shares of Lantheus in the 4th quarter worth approximately $27,000. Summit Securities Group LLC acquired a new position in Lantheus during the 4th quarter worth $37,000. Parkside Financial Bank & Trust lifted its holdings in Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock worth $76,000 after buying an additional 280 shares in the last quarter. UMB Bank n.a. lifted its holdings in Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider’s stock worth $92,000 after buying an additional 381 shares in the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new position in Lantheus during the 4th quarter worth $125,000. 99.06% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 26,066 shares of the company’s stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the sale, the director now owns 318,650 shares in the company, valued at $24,481,879.50. This represents a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07% decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by insiders.

Lantheus Trading Down 2.9%

NASDAQ LNTH opened at $77.83 on Friday. Lantheus Holdings, Inc. has a 1-year low of $73.11 and a 1-year high of $126.89. The company has a 50 day moving average of $88.82 and a 200-day moving average of $91.38. The company has a market cap of $5.38 billion, a price-to-earnings ratio of 12.95 and a beta of 0.11.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business’s revenue was up .8% compared to the same quarter last year. During the same period last year, the business earned $1.69 earnings per share. On average, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analyst Weigh In

LNTH has been the topic of several research reports. B. Riley reduced their price objective on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a report on Friday, March 21st. Wall Street Zen raised Lantheus from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Finally, Truist Financial cut their price target on Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lantheus has an average rating of “Buy” and an average price target of $132.67.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.